In an abnormal fibrinogen (fibrinogen Naples) associated with congenital thrombophilia we have identified a single base substitution (G -A) in the B,8 chain gene that results in an amino acid substitution of alanine by threonine at position 68 in the BB chain of fibrinogen. The propositus and two siblings were found to be homozygous for the mutation, whereas the parents and another sibling were found to be heterozygous. Individuals homozygous for the defect had a severe history of both arterial and venous thrombosis; heterozygous individuals had no clinical symptoms. The three homozygotes had a prolonged thrombin clotting time in plasma, whereas the heterozygotes had a normal thrombin clotting time. Fibrinopeptide A and B (FpA and FpB) release from purified fibrinogen by human a-thrombin was delayed in both the homozygous propositus and a heterozygous family member. Release of FpA from the normal and abnormal amino-terminal disulfide knot (NDSK) corresponded to that found with the intact fibrinogens, indicating a decreased interaction of thrombin with the NDSK part of fibrinogen Naples. Binding studies showed that fibrin from homozygous abnormal fibrinogen bound < 10% of active site inhibited athrombin as compared with normal fibrin, while fibrin formed from heterozygous abnormal fibrinogen bound -50% of athrombin. These results suggest that the mutation of BB Ala 68 --Thr affects the binding of a-thrombin to fibrin, and that defective binding results in a decreased release of FpA and FpB in both homozygous and heterozygous abnormal fibrinogens. (J. Clin. Invest. 1992. 90:238-244.)
Introduction
The fibrinogen molecule is involved in the final phase ofblood coagulation and consists ofpairs ofAa, Bf, and y chains linked by 29 disulphide bonds (1) . The conversion of fibrinogen to fibrin is initiated by thrombin catalyzed cleavage offibrinopep-with fibrin(ogen) involves multiple sites on both thrombin and fibrin(ogen). An important domain of fibrinogen that interacts with the catalytic'site of thrombin is located in the Aa chain between amino acids 1 and 23 (2) (3) (4) (5) (6) . The interaction ofthrombin with fibrin through a site independent of the catalytic site (anion-binding exosite) (7) (8) (9) (10) (11) (12) is located in a cyanogen bromide (CNBr)-derived fragment of the amino-terminal part of the fibrin(ogen) molecule amino-terminal disulfide knot (NDSK) (13) (14) (15) . Binding of a-thrombin to fibrin by the anion-binding exosite results in the removal of thrombin from solution (7, 9) . It has been proposed that this interaction plays an important role in the regulation of thrombus formation in vivo by limiting the amount of free active thrombin in the circulation (7) . Congenitally abnormal fibrinogens are valuable tools for structure-function studies ofhuman fibrinogen. They also provide a basis for correlating the molecular defect with the clinical symptoms of affected individuals. Many abnormal fibrinogens have been described (16) , of which a large number show defective release of fibrinopeptides due to a mutation at or near the thrombin cleaved bond (17) (18) (19) (20) . The structural defect of an abnormal fibrinogen (fibrinogen New York I) with impaired thrombin binding to fibrin (21) has been determined. This fibrinogen lacks amino, acids in the Bfl-chain (22) . The patient, who was shown to be heterozygous, suffered from thrombotic episodes (23) . Fibrinogen Naples (Milano II) (24, 25) is another abnormal fibrinogen associated with congenital thrombophilia. Preliminary work on fibrinogen Naples demonstrated a defective interaction between bovine thrombin and fibrin of the propositus (24) . In this article we report the structural defect offibrinogen Naples, inferred from genetic analysis of patient DNA using the polymerase chain reaction (PCR) (26) . The presence ofthe mutation in the family members, the binding of human a-thrombin to fibrin, and the relationship between the defect and clinical symptoms were also determined.
Methods
Patients. The propositus (11.3) Coagulation studies on plasma. Blood was collected by venipuncture and anticoagulated with 0.1 vol of 0.11 M trisodium citrate. Plasma was prepared by centrifugation at 2,300 g for 30 min at 4°C.
Thrombin clotting times were performed at 37°C with 200 Al ofplasma and 50 Ml of human a-thrombin (1,000 National Institutes of Health (NIH) U/mg; Protogen, Lafelfingen, Switzerland), dissolved in 0.15 M NaCl containing 0.025% (wt/vol) gelatin to a concentration of 25 NIH U/ml. Reptilase (Boehringer Mannheim, Mannheim, FRG) clotting time was performed as described (24) . Fibrinogen concentration was determined functionally according to Clauss (27) and immunologically according to Mancini et al. (28) .
Purification offibrinogen and NDSK Fibrinogen was purified from plasma as described (29) and dialyzed against PBS for 24 h at 4°C. NDSK was purified after CNBr digestion of purified fibrinogen (30) by a fast protein liquid chromatography (FPLC) system equipped with a Superose 12 column (Pharmacia, Uppsala, Sweden). The column was equilibrated with 10% acetic acid containing 0.1 M NaCl and run at a flow rate of 1.0 ml/min. The CNBr digest, 6 mg of protein in 0.3 ml, was injected and 0.5-ml fractions were collected. Fractions 12-15 ( Fig.  1 ) were pooled and analyzed on SDS-PAGE (31). The purified fibrinogen NDSK showed an Mr -65,000 and a purity of -90% (Fig. 1) . Pooled fractions were dialyzed against distilled water, lyophilized, and dissolved in PBS to a concentration of 0.7 mg/ml. The fibrinogen and NDSK concentrations were measured spectrophotometrically at 280 nm (fibrinogen, A'%"," = 15.0 (32), NDSK, A"%,"mn = 12.0 [calculated from amino acid composition]); the yield of this purification was -65%.
Release offlbrinopeptidesfromflbrinogen and NDSK. The rate of FpA and FpB release was determined at 37°C with 100 Ml offibrinogen solution (4.0 mg/ml) or NDSK solution (0.7 mg/ml) and 10 M ofeither I NIH U/ml human a-thrombin or 1:30 diluted Reptilase. The reactions were stopped at various times by placing the samples in a boiling water bath for 2 min. The samples were centrifuged at 12,000 g for 10 min, and 50 Ml of the supernatant was analyzed by HPLC (LKB Produkter, Bromma, Sweden) on a C-18 reversed-phase column (Chrompack, Middelburg, The Netherlands) (24, 33) . The amount ofFpA and FpB released was determined by measuring the peak area.
Fibrin polymerization. Purified fibrinogen was dissolved in PBS to a concentration of 2.0 mg/ml. 1 ml of this solution was clotted by adding 0.1 ml ofhuman a-thrombin (25 NIH U/ml) or undiluted Reptilase over a period of 5 h at 37°C. The fibrin was collected by centrifugation, washed four times with PBS, and subsequently dissolved in 20 mM acetic acid to a concentration of2.0 mg/ml. [34] ). The amidolytic activity ofinhibited thrombin, determined by using the synthetic substrate S-2238 (KabiVitrum, Stockholm, Sweden) according to the manufacturer's instructions, was < 0.05% of the original activity. The relative a-, ,B-, and y-thrombin content was determined by SDS-PAGE (31) followed by autoradiography. The amount of a-thrombin was > 95% (Fig. 2) . To prevent nonspecific adsorption, gelatin (final concentration 0.1% wt/vol) was added to the thrombin solution, and this solution was stored at -70°C.
['"C]DFP a-thrombin binding to fibrin. Fibrinogen was dialyzed against 50 mM Tris/HCI, pH 7.5, 100 mM NaCl, and diluted to 0.5 mg/ml. Part of this fibrinogen solution was radiolabeled with 125I (Amersham, Buckinghamshire, UK) as described (35). To 0.15 ml of fibrinogen, 50 ul ofsolutions containing different amounts of['4C]DFP inhibited a-thrombin diluted in 50 mM Tris/HCI, pH 7.5, 100 mM NaCI, 0.1% (wt/vol) gelatin were added. Subsequently, fibrin formation was induced by incubating with 10 ,l of undiluted Reptilase solution for 30 min. Fibrin was collected by centrifugation for 10 min at 12,000 g. The pellet was washed three times with 0.5 ml 50 mM Tris/ HCI, pH 7.5, 100 mM NaCl, and dissolved in 0.2 ml of 50 mM acetic acid. The sample was mixed with 3.0 ml of scintillation fluid (Ultima Gold, Packard Instrument Co., Inc., Downers Grove, IL) and 14C was counted (Tricarb 1900 CA, Packard Instrument Co., Inc.). The amount of fibrin formed was determined in parallel experiments containing trace amounts of '25I-fibrinogen. After dissolving the fibrin in acetic acid, the amount of radioactivity was counted in a y counter (Cobra, Packard Instrument Co., Inc.). Under these conditions normal fibrinogen and fibrinogen Naples II.3 and II.4 were 93-96% clottable.
Fibrin stimulation oftissue-type plasminogen activator (t-PA). mers, prepared as described for fibrin polymerization, was assayed as described previously (36) .
PCR. Genomic DNA was isolated from blood cells as described (37) . Oligonucleotides were synthesized on a model 380A DNA synthesizer (Applied Biosystems, Inc., Foster City, CA). Oligonucleotides ala(5'GCAGATAGTGGTGAAGGTGAC3') and a lb(5'GTTATTG-GCTGAGGAAAAATCGCC3') were used to amplify the part of the a-chain gene, coding for amino acids 1-95. Oligonucleotides #l a(5'GGTGTTGGAATAGTTACATTCC3') and fl b(5'GGTGTG-TGAGTTCTTCTGGA3') were used to amplify the part of the Bflchain gene, coding for amino acids 9-209. fl2a(5'GCCTCTAAGGTT-GTAGGAATTCTTCAG3')andfl2b(5'ATCAGTGCACCCACCAAG-TCTGGG3') were used to amplify the ,B-gene segment coding for amino acids 9-72. Oligonucleotidesy Ila(5'GCTCTTCACAAAACG-TTGTTTAAAATGGAATTCTGG3')andy lb(5'CAGTCTTGCAGA-GCAAATTAAAACAAAAATCCTTAC3') were used to amplify the part of the y-chain gene coding for amino acids 1-108. Amplification by PCR (26) was performed in a 1O0-,l reaction volume containing 1 gg of genomic DNA, 0.2 mM of each dNTP (Pharmacia), 0.2 ,uM of each primer in lx reaction buffer (10 mM Tris/HCl, pH 8.3 at 25°C, 50 mM KCI, 3.0 mM MgCl2 and 0.001% (wt/vol) gelatin). The DNA was denatured at 95°C for 8 min and 2.0 U Taq DNA polymerase (Perkin-Elmer Cetus, Emeryville, CA) were added. Cycles consisted of a 1-min 95°C, 0.5-min 60°C, and 3-min 70°C incubation. After 30 cycles 5 gul of the sample was analyzed on a 1.0% agarose gel (A-601 3, Sigma Chemical Co., St. Louis, MO).
Direct sequencing PCR fragments. PCR samples were run on a 1%
(wt/vol) ultralow gelling agarose gel (A-5030, Sigma Chemical Co.). The band with the appropriate size, as predicted by the genomic sequence ofthe Aa (16), Bf (16, 38) , andy chain genes (36), was cut out of the gel and heated to 65°C. 1 gil of the melted agarose, containing -10 ng of DNA, was mixed with 1 gl of the appropriate PCR primer (60 ng), and 2 ,ul of SX sequence buffer (T7 sequence kit, Promega Corp., Madison, WI), the volume was brought up to 10 gl with distilled water. The mixture was heated to 95°C for 3 min and immediately put on ice. Labeling and termination reactions were performed using the T7 DNA sequence kit (Promega Corp.) according to the manufacturer's instruction.
Southern blot analysis offamily members and normal population.
Amplified fragments of the BB chain gene containing the sequence coding for amino acids 9-72 (-50 ng) were run on a 2% (wt/vol) agarose gel (A-6013, Sigma Chemical Co.). The gel was washed (twice for 15 min) with 0.5 M NaOH, 1.5 M NaCl, and the denatured DNA was transferred to a nylon membrane (Hybond N, Amersham) using the Vacugene blotting system (LKB Produkter). 100 ng of sequencespecific oligonucleotides (f-normal: 5TGTCTTCACGCTGACC-CAG3 and f-Naples: 5TGTCTTCACACTGACCCAG3') were radiolabeled with T4 polynucleotide kinase (Gibco BRL, Breda, The Netherlands) according to the manufacturer's instructions, using [y-32P]ATP (3,000 Ci/mmol, Amersham). The blots were washed with 2x SSC (I x SSC contains 0.15 M NaCl and 0.015 M Na3C6H507) and hybridized with the labeled oligonucleotides in 40 ml of 7% SDS, 0.36 M Na2HPO4, 0.14 M NaH2PO4, and 10 mM EDTA for 4 h at 42°C. Blots were washed three times for 30 min at 58°C with 6x SSC containing 0.5% (wt/vol) SDS, and exposed to x-ray film (X-AR, Eastman Kodak Co., Rochester, NY) for 16 h.
Results
Coagulation studies on plasma. Fibrinopeptide release from fibrinogen. Fig. 3 shows the thrombin-catalyzed release of the FpA and FpB from normal fibrinogen, fibrinogen Naples 11.3 (propositus with prolonged thrombin clotting time), and Naples II.4 (sibling with normal thrombin clotting time). FpA release (Fig. 3 A) from both fibrinogens Naples 11.3 and 11.4 is strongly delayed as compared with normal fibrinogen. There is a large difference in the amount of FpA released after 60 min from normal fibrinogen (100%) and from fibrinogens Naples 11.4 (63%) and Naples 11.3 (24%). Fibrinogen Naples I.3 also showed a lag of -10 min before any FpA could be detected; fibrinogen Naples II.4 and normal fibrinogen did not show this lag period. The release of FpB (Fig. 3 B) ._._0 identical to the release from intact normal and Naples 11.3 fibrinogen, respectively (compare Fig. 4 with Fig. 3 A) . The release of FpB from NDSK Naples I.3 was delayed as compared with normal NDSK. In contrast to the FpA release, the FpB release from normal NDSK is slower than the FpB release from intact normal fibrinogen (compare Fig. 4 with Fig.  3 B) . However, the FpB release of NDSK Naples II.3 was approximately the same as the FpB release of intact fibrinogen Naples II.3 (compare Fig. 4 with Fig. 3 B) .
The release of FpA by Reptilase from NDSK Naples II.3 was the same as that from normal NDSK (data not shown). ported previously (24) , and indicate that the mutation in fibrinogen Naples does not affect the fibrin polymerization.
Binding ofactive-site inhibited human a-thrombin tofibrin. Fibrin stimulation oft-PA-inducedplasminogen activation. The stimulatory effect of fibrin Naples 11.3 on t-PA-induced plasminogen activation was normal, as compared with fibrin prepared from normal fibrinogen, by both Reptilase and thrombin (data not shown). These results indicate that the interaction among fibrin Naples, t-PA, and plasminogen in a purified system is not affected by the mutation in fibrinogen Naples. This concurs with the previously described normal interaction between fibrin Naples and several components of the fibrinolytic system in plasma (24) . It also indicates that the observed thrombophilia in the affected individuals is not related to defective fibrinolysis.
Amplification and direct sequencing ofgenomic DNA fragments. Based on the evidence of fibrinopeptide release by thrombin, which showed that the defect was located in the NDSK part of fibrinogen Naples, we amplified the genomic DNA which codes for NDSK, specifically amino acids Aa 1-51, B/3 1-1 18, and y 1-79 of the fibrinogen molecule. After amplification, fragments with the sizes predicted from the genomic DNA sequences for the human fibrinogen Aa, B/3, and y chain genes (16, 38, 39) were sequenced. The fragments containing the Aa or My gene sequence were completely normal, whereas the B/3 fragment ofNaples I.3 had a single base substitution (Fig. 6 ) in the codon normally coding for alanine at position 68. This mutation changed the codon GCT (alanine) to ACT which codes for threonine. The normal sequence was completely missing in Naples II.3, indicating that the propositus was homozygous for this mutation. Detection ofmutation infamily members and normal individuals. The amplified B/3 fragments of the family members were hybridized with two synthetic oligonucleotides, one with the normal sequence (/3-normal) and the other with the sequence found in fibrinogen Naples (,3-Naples). Fig. 7 shows that the amplified B/3 fragments of Naples 1.1, 1.2, and 11.4 hybridize with both oligonucleotides, indicating that the asymptomatic family members are heterozygous for the mutation found in the B/3 fragment. Amplified B/3 fragments of Naples I. 1, 11.2, and 11.3 hybridized only with the ,8-Naples oligonucleotide, showing that the symptomatic family members were homozygous for the mutation. The corresponding fragment of 120 normal individuals hybridized only with the /3-normal oligonucleotide (data not shown), indicating that the mutation was not a common polymorphism.
Discussion
The mutation in fibrinogen Naples is associated with a defective release of FpA and FpB by thrombin. Because this defect was present in the purified NDSK fragment of fibrinogen Naples, we amplified and sequenced the genomic DNA segments encoding the NDSK fragments Aa, B/3, and y chains. Sequence analysis of the amplified products demonstrated that the propositus (11.3) was homozygous for a single base substitution in the codon for B/3 Ala 68 (GCT) resulting in a Thr (ACT) at this position. Southern blot analysis using sequence specific oligonucleotides showed that all three asymptomatic family members were heterozygous for the mutation while the three symptomatic members (including the propositus) were homozygous. This indicates that the homozygous mutation (B/3 68 Ala--oThr) is associated with thrombophilia, and that this type of dysfibrinogenemia is clinically recessive. By using fibrinogen purified from the homozygous propositus, a-thrombin-catalyzed FpA release was delayed relative to normal fibrinogen. The rate of FpA release from fibrinogen isolated from a heterozygous family member (II.4) was approximately half that of normal, indicating that heterozygous individuals have both normal and abnormal molecules. Human a-thrombin-catalyzed release ofFpA from the purified NDSK fragment of normal fibrinogen was identical to that of intact fibrinogen. As previously reported (2, 3) , this provides evidence that the NDSK fragment contains all the essential information for an effective interaction ofthrombin with fibrinogen. Analogously, NDSK from the homozygous fibrinogen Naples I.3 had the same decreased rate of FpA release by a-thrombin as intact fibrinogen Naples 11.3, indicating that the defective domain is located in the NDSK part of the fibrinogen Naples molecule. The release of FpA by Reptilase from fibrinogen Naples and NDSK Naples 11.3 was normal, indicating that the mutation did not affect the substrate cleavage site ofFpA in the Aa-chain.
The rate of FpB release from homozygous fibrinogen Naples 11.3 was also strongly delayed as compared to normal fibrinogen. The FpB release from NDSK Naples 11.3 was approximately the same as from intact fibrinogen Naples 11.3, which is in contrast with the slower release of FpB from normal NDSK as compared with normal fibrinogen. The reduced release of FpB from normal NDSK as compared with normal intact fibrinogen, can be explained by the accelerating effect of fibrin polymerization on FpB release (40) (41) (42) (43) , which is absent when using NDSK. The similar release of FpB from NDSK Naples II.3 and intact fibrinogen Naples 11.3 suggests that this accelerating effect of fibrin polymerization is absent in fibrin Naples.
Active site-inhibited thrombin binds to fibrin by a site independent of the catalytic site designated the anion-binding exosite (7) (8) (9) (10) (11) (12) . Active site-inhibited human a-thrombin bound to normal fibrin formed by Reptilase. In contrast, thrombin binding to fibrin Naples 11.3 was very low whereas thrombin binding to fibrin Naples II. 4 The loss of the anion-binding exosite from a-thrombin in the formation of f-and y-thrombins, results in a reduced clotting activity of f-and y-thrombins for fibrinogen (9, 13) . This suggests that the reduced fibrinopeptide release observed in fibrinogen Naples could be fully accounted for by the decreased noncatalytic binding of a-thrombin to fibrinogen Naples. However, the possibility of influence by amino acid substitution in fibrinogen Naples on the catalytic binding of a-thrombin cannot be ruled out.
Fibrinogen New York I (23) also showed a decreased release of FpA and FpB, and a defective binding of thrombin (24) . In contrast to fibrinogen Naples, the defect in fibrinogen New York I is extensive, in that amino acids Bol 9-72 are deleted. This large deletion is likely to have multiple effects on the defective fibrinogen structure, particularly because Bo Cys 65, which normally forms a disulphide bond with Aa Cys 36, is missing. Without information about the three-dimensional structure of NDSK, it is difficult to determine the exact influence of the BJ3 68 Ala -> Thr substitution on the binding to thrombin. One possible explanation is that Bo 68 alanine participates in a nonpolar interaction with thrombin and that this is disrupted by threonine. Alternatively, the slightly larger side chain of threonine could lead to incorrect folding or disulfide bond formation of this part of the fibrinogen molecule, preventing thrombin binding.
It has been suggested that thrombin binding to fibrin is a mechanism that prevents active thrombin from existing free in the circulation (7). In the absence of this binding, free active thrombin in the circulation results in excessive coagulation and/or platelet aggregation which in its turn can lead to thrombosis. From the dramatic history of thrombophilia in the family with fibrinogen Naples and the genetic analysis of the family, it is clear that the occurrence of thrombosis is related to the defect in fibrinogen Naples only in homozygous family members. The mutation in fibrinogen Naples (Bo 68 Ala --Thr) prevents thrombin binding to fibrin and is correlated with thrombophilia. These results demonstrate that thrombin binding to fibrin is an important in vivo mechanism to limit the presence of free active thrombin in circulation and to prevent excessive coagulation and/or platelet activation leading to thrombosis.
